• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

AI team at In­sil­i­co gets some ma­jor league back­ing from Chi­na as Alex Zha­voronkov builds glob­al net­work

8 years ago
Financing
China

Af­ter cash fun­nel­ing scan­dal, biotech bil­lion­aire Soon-Sh­iong charges on with Nant IPO

8 years ago
People
Financing

Bit­ter­ly op­posed old guard at Take­da wages a last-ditch fight to block 'for­eign blood­'s' $62B Shire buy­out

8 years ago
Deals

Alex­ion cau­tious­ly steps over to the C6 path­way with an ear­ly-stage de­vel­op­ment deal tied to buy­out op­tion

8 years ago
Pharma

Sanofi builds on mR­NA al­liances with an $805M pact for Ron Re­naud’s Trans­late Bio

8 years ago
R&D
Pharma

Ab­b­Vie, Roche post a big win with a block­buster FDA OK for Ven­clex­ta/Rit­ux­an com­bo for leukemia

8 years ago
Pharma

Strike two: Vi­cal says an­oth­er one of its vac­cines has crashed and burned in PhII

8 years ago
R&D

Vi­su­al­ize: AS­CO 2018's win­ners and losers

8 years ago
R&D
Pharma

Ru­bius snaps up No­var­tis vet Pablo Cagnoni as CEO; MiMedx dumps two ex­ecs fol­low­ing in­ter­nal in­ves­ti­ga­tion

8 years ago
Peer Review

Al­ny­lam's up­dat­ed lumasir­an da­ta points to PhI­II short track; Genen­tech snatch­es fourth ap­proval for Rit­ux­an

8 years ago
News Briefing

Af­ter snatch­ing up Shire's can­cer unit, French phar­ma gi­ant Servi­er to ex­pand US pres­ence with Kendall Square ...

8 years ago
R&D

Ex-con Sam Wak­sal's start­up prices IPO, join­ing pa­rade of biotechs with Nas­daq news

8 years ago
Financing

Sound fa­mil­iar? Chi­na/US biotech hy­brid lands rights to can­cer drugs, cash and a team of de­vel­op­ment vets to launch ...

8 years ago
Financing
Startups

Di­a­betes gi­ant No­vo said to con­sid­er up to 3,000 lay­offs as US pric­ing storms gath­er: re­port

8 years ago
R&D
Pharma

Re­lo­cat­ing its US HQ to Boston, French phar­ma Ipsen to add 250 jobs

8 years ago
R&D
Pharma

Gates Foun­da­tion sets up biotech-like in­sti­tute in hands-on ef­fort to spur drug de­vel­op­ment for ne­glect­ed dis­eases

8 years ago
R&D
Pharma

Pro­teosta­sis shares whacked hard as CF drug falls short; Ad­vax­is ax­es tri­al plans in wake of a clin­i­cal hold

8 years ago
News Briefing

On an ex­ec­u­tive hir­ing spree, Sarep­ta snags Bio­gen's Gilmore O'Neill as new CMO

8 years ago
People

That big Bio­gen deal you were wait­ing for? Keep wait­ing

8 years ago
Pharma

Mega-block­buster? Pfiz­er lines up for a snap re­view of its PARP drug ta­la­zoparib — and a launch in­to a crowd­ed ...

8 years ago
Pharma

No­to­ri­ous ac­tivist in­vestor Carl Ic­ahn buys small stake in Al­ler­gan

8 years ago
People

Tilt­ing at vac­cines gi­ants, SutroVax fu­els up on a $170M-plus quest to vault past the world's best-sell­ing vac­cine

8 years ago
Financing

Man­u­fac­tur­ing ex­perts at Hangzhou Just Bio­ther­a­peu­tics bank $35M for stealthy R&D in Chi­na and the US

8 years ago
Financing
China

Bio­gen, Ei­sai BACE drug cuts amy­loid be­ta in the brain, but there’s no hard da­ta to show it does any­thing im­por­tant ...

8 years ago
R&D
First page Previous page 1037103810391040104110421043 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times